Citadel Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Citadel Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.73M	Sell	492,200 -166,000	-25%	-$531K	﹤0.01%	6406
2025 Q4	$1.8M	Buy	658,200 +11,000	+2%	+$25.4K	﹤0.01%	6144
2025 Q3	$1.4M	Buy	647,200 +70,000	+12%	+$165K	﹤0.01%	6796
2025 Q2	$993K	Sell	577,200 -97,800	-14%	-$243K	﹤0.01%	7104
2025 Q1	$2.25M	Sell	675,000 -321,900	-32%	-$1.66M	﹤0.01%	5315
2024 Q4	$7.38M	Buy	996,900 +340,200	+52%	+$3.15M	﹤0.01%	3367
2024 Q3	$6.17M	Buy	656,700 +232,900	+55%	+$2.21M	﹤0.01%	3618
2024 Q2	$3.4M	Buy	423,800 +47,800	+13%	+$512K	﹤0.01%	4363
2024 Q1	$5.57M	Sell	376,000 -11,400	-3%	-$133K	﹤0.01%	3783
2023 Q4	$3.15M	Sell	387,400 -146,900	-27%	-$769K	﹤0.01%	4562
2023 Q3	$2.43M	Buy	534,300 +353,700	+196%	+$2.31M	﹤0.01%	4868
2023 Q2	$1.27M	Buy	180,600 +69,000	+62%	+$494K	﹤0.01%	5966
2023 Q1	$682K	Sell	111,600 -19,200	-15%	-$132K	﹤0.01%	7636
2022 Q4	$836K	Buy	130,800 +59,800	+84%	+$467K	﹤0.01%	7160
2022 Q3	$680K	Sell	71,000 -31,500	-31%	-$363K	﹤0.01%	7801
2022 Q2	$1.13M	Sell	102,500 -98,100	-49%	-$1.29M	﹤0.01%	6747
2022 Q1	$3.34M	Buy	200,600 +31,600	+19%	+$489K	﹤0.01%	4963
2021 Q4	$3.23M	Sell	169,000 -17,300	-9%	-$381K	﹤0.01%	5191
2021 Q3	$4.59M	Buy	186,300 +6,300	+4%	+$148K	﹤0.01%	4462
2021 Q2	$4.68M	Buy	180,000 +9,800	+6%	+$255K	﹤0.01%	4586
2021 Q1	$5.39M	Buy	170,200 +40,800	+32%	+$1.69M	﹤0.01%	4095
2020 Q4	$6M	Buy	129,400 +88,400	+216%	+$3.51M	﹤0.01%	3373
2020 Q3	$1.35M	Sell	41,000 -61,900	-60%	-$1.9M	﹤0.01%	5469
2020 Q2	$2.83M	Buy	102,900 +83,500	+430%	+$2.75M	﹤0.01%	3962
2020 Q1	$581K	Sell	19,400 -1,900	-9%	-$50.4K	﹤0.01%	6222
2019 Q4	$590K	Sell	21,300 -600	-3%	-$13.6K	﹤0.01%	6553
2019 Q3	$399K	Sell	21,900 -5,700	-21%	-$126K	﹤0.01%	7136
2019 Q2	$677K	Buy	+27,600	New	+$416K	﹤0.01%	6326
2019 Q1	–	Sell	-18,100	Closed	-$160K	–	9568
2018 Q4	$160K	Sell	18,100 -4,500	-20%	-$43.4K	﹤0.01%	8022
2018 Q3	$254K	Buy	22,600 +7,000	+45%	+$99.4K	﹤0.01%	7843
2018 Q2	$200K	Buy	15,600 +4,400	+39%	+$64.3K	﹤0.01%	7889
2018 Q1	$189K	Buy	+11,200	New	+$170K	﹤0.01%	7397
2017 Q4	–	Sell	-10,800	Closed	-$84K	–	8200
2017 Q3	$84K	Buy	+10,800	New	+$68.3K	﹤0.01%	7084
2016 Q3	–	Sell	-10,200	Closed	-$83K	–	7458
2016 Q2	$83K	Buy	+10,200	New	+$64.1K	﹤0.01%	6267
2016 Q1	–	Sell	-1,300	Closed	-$10K	–	7338
2015 Q4	$10K	Buy	+1,300	New	+$9.02K	﹤0.01%	8270
2015 Q3	–	Sell	-4,900	Closed	-$45K	–	9052
2015 Q2	$45K	Buy	+4,900	New	+$54.7K	﹤0.01%	7715

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Citadel Advisors's IOVA Position: Q1 2026 in Review

Citadel Advisors reduced its Iovance Biotherapeutics (IOVA) stake by 17% in Q1 2026, selling an estimated $1.7M and leaving 2,611,345 shares worth $9.17M. The position accounts for ﹤0.01% of the portfolio, ranked #3375.

Citadel Advisors first reported a position in IOVA in Q2 2015 and has held it in 42 quarters since. The position peaked at $61.9M in Q2 2021. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Citadel Advisors held 2,611,345 shares of Iovance Biotherapeutics worth $9.17M as of Q1 2026.
Citadel Advisors sold 531,746 Iovance Biotherapeutics shares in Q1 2026, an estimated $1.7M.
Iovance Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3375 holding.
Citadel Advisors first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 42 quarters since.
Citadel Advisors's Iovance Biotherapeutics position peaked at $61.9M in Q2 2021.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.